New York State Common Retirement Fund Sells 5,000 Shares of Amedisys, Inc. (NASDAQ:AMED)

New York State Common Retirement Fund cut its stake in shares of Amedisys, Inc. (NASDAQ:AMED) by 14.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,348 shares of the health services provider’s stock after selling 5,000 shares during the period. New York State Common Retirement Fund owned about 0.09% of Amedisys worth $2,885,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Commonwealth Equity Services LLC raised its holdings in shares of Amedisys by 2.9% in the third quarter. Commonwealth Equity Services LLC now owns 3,896 shares of the health services provider’s stock valued at $364,000 after purchasing an additional 110 shares during the last quarter. Xponance Inc. increased its stake in Amedisys by 3.2% in the 3rd quarter. Xponance Inc. now owns 4,076 shares of the health services provider’s stock valued at $381,000 after buying an additional 125 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Amedisys by 1.5% during the 3rd quarter. Arizona State Retirement System now owns 9,284 shares of the health services provider’s stock worth $867,000 after buying an additional 141 shares in the last quarter. Argonautica Private Wealth Management Inc. boosted its stake in shares of Amedisys by 6.1% in the 3rd quarter. Argonautica Private Wealth Management Inc. now owns 3,003 shares of the health services provider’s stock worth $280,000 after buying an additional 172 shares during the last quarter. Finally, Paralel Advisors LLC increased its position in shares of Amedisys by 1.1% during the third quarter. Paralel Advisors LLC now owns 26,002 shares of the health services provider’s stock valued at $2,429,000 after acquiring an additional 295 shares during the last quarter. 94.36% of the stock is owned by hedge funds and other institutional investors.

Amedisys Stock Performance

NASDAQ AMED opened at $92.34 on Tuesday. The firm has a market cap of $3.02 billion, a P/E ratio of -144.28, a price-to-earnings-growth ratio of 3.43 and a beta of 0.84. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.31. The company’s 50 day moving average is $92.36 and its 200-day moving average is $93.33. Amedisys, Inc. has a 12-month low of $73.10 and a 12-month high of $96.44.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, April 24th. The health services provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The firm had revenue of $571.41 million during the quarter, compared to analyst estimates of $565.38 million. During the same period last year, the company earned $1.00 earnings per share. The business’s revenue for the quarter was up 2.7% on a year-over-year basis. Sell-side analysts predict that Amedisys, Inc. will post 4.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. StockNews.com upgraded Amedisys from a “hold” rating to a “buy” rating in a research note on Saturday. Royal Bank of Canada raised their price objective on shares of Amedisys from $97.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 25th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $101.00 target price on shares of Amedisys in a research note on Thursday, April 25th. Finally, Raymond James restated a “market perform” rating on shares of Amedisys in a research note on Tuesday, March 26th. Seven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $100.80.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.